Stock RO ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Market Closed - Swiss Exchange
Other stock markets
 11:31:51 2024-04-24 am EDT 		5-day change 1st Jan Change
239.2 CHF -4.40% Intraday chart for Roche Holding AG +0.59% -8.49%
Apr. 24 ROCHE HOLDINGS AG : DZ Bank reiterates its Buy rating ZD
Apr. 24 Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red MT

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • With an enterprise value anticipated at 3.28 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROCHE HOLDING AG Stock Roche Holding AG
-8.49% 204B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 672B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.87% 570B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 321B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.28% 300B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.09% 217B
B+
NOVARTIS AG Stock Novartis AG
+5.01% 199B
B-
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
C+
AMGEN INC. Stock Amgen Inc.
-5.21% 147B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RO Stock
  5. Ratings Roche Holding AG